On the basis of follow-up data from the BFORE, DASISION, and ENESTnd trials, a second-generation TKI (bosutinib, dasatinib, or nilotinib) is the preferred treatment option for patients with intermediate- or high-risk chronic phase CML. According to NCCN guidelines, the first-generation TKI, imatinib, is another recommended (but not preferred) option.
Learn more about treatment protocols for intermediate- or high-risk CML.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Chronic Myelogenous Leukemia Management - Medscape - Sep 21, 2022.